1Mugla Sitki Kocman University Faculty of Medicine, Department of Internal Medicine, Mugla
2Mugla Sitki Kocman University Faculty of Medicine, Department of Internal Medicine, Division of Gastroentero-hepatology, Mugla
3Mugla Sitki Kocman University Faculty of Medicine, Department of Oncology
Purpose: In this pilot study we investigated whether serum levels of uric acid, the final breakdown product of purine metabolism, might influence cancer-related events in stage II and III colorectal cancer patients. Material and methods: In this cross-sectional retrospective study, a total of 150 stage II and III colorectal adenocarcinoma patients with no exclusion criteria were included. Serum uric acid levels of the patients measured at diagnosis and demographic, clinical, laboratory analyses were performed and histologically features recorded. Patients were stratified into quartiles according to serum uric acid level with different cut-off values. Results: The mean serum uric acid level of all patients was determined o be 6.97±2.87 md/dL (range, 3.1-12.4). Median follow-up time was 98 (range 9-98) months and the proportion of patients who did not relapse was 22%. It was determined that majority of the patients who had serum uric acid levels over 8.37 mg/dL had stage IIIB lesions, were smokers, were among those who lost weight, with metastasis to the liver and with significantly leukocyte and platelet counts. Conclusions: Serum uric acid levels measured at the time of diagnosis may be associated with cancer-related events so we can conclude a prognostic value of increase in colorectal cancer patients.